1.London School of Economics. Tender loving care? Purchasing medicines for continuing therapeutic improvement and better health outcomes. 2016. http://eprints.lse.ac.uk/67824/ (accessed November 16, 2016).
2.Schnipper, LE, Bastian, A. New frameworks to assess value of cancer care: Strengths and limitations. Oncologist. 2016;21:654–658.
3.Schnipper, LE, Davidson, NE, Wollins, DS, et al. American Society of Clinical Oncology Statement: A conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33:2563–2577.
4.Cherny, NI, Sullivan, R, Dafni, U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol. 2015;26:1547–1573.
5.Cox, C, Kamal, R, Jankiewicz, A, et al. Recent trends in prescription drug costs. JAMA. 2016;315:1326.
6.Penington, R, Stubbings, JA. Evaluation of specialty drug price trends using data from retrospective pharmacy sales transactions. J Manag Care Spec Pharm. 2016;22:1010–1017.
7.Aronson, JK, Ferner, RE, Hughes, DA. Defining rewardable innovation in drug therapy. Nat Rev Drug Discov. 2012;11:253–255.
8.Claxton, K, Martin, S, Soares, M, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess. 2015;19:1–503.
9.McCabe, C, Bergmann, L, Bosanquet, N, et al. Market and patient access to new oncology products in Europe: A current, multidisciplinary perspective. Ann Oncol. 2009;20:403–412.
10.Buxton, MJ, Chambers, JD. What values do the public want their health care systems to use in evaluating technologies? Eur J Health Econ. 2011;12:285–288.
11.Kesselheim, AS, Wang, B, Avorn, J. Defining innovativeness in drug development: A systematic review. Clin Pharmacol Ther. 2013;94:336–348.
12.Andria, B, Auriemma, L, Attanasio, C, et al. The impact of innovation for biotech drugs: An Italian analysis of products licensed in Europe between 2004 and 2011. Eur J Hosp Pharm. 2013;20:328–335.
13.Mol, PGM, Arnardottir, AH, Motola, D, et al. Post-approval safety issues with innovative drugs: A European cohort study. Drug Safety. 2013;36:1105–1115.
14.Motola, D, De Ponti, F, Rossi, P, et al. Therapeutic innovation in the European Union: Analysis of the drugs approved by the EMEA between 1995 and 2003. Br J Clin Pharmacol. 2005;59:475–478.
15.Motola, D, De Ponti, F, Poluzzi, E, et al. An update on the first decade of the European centralized procedure: How many innovative drugs? Br J Clin Pharmacol. 2006;62:610–616.
16.Bryan, S, Lee, H, Mitton, C. ‘Innovation’ in health care coverage decisions: All talk and no substance? J Health Serv Res Policy. 2013;18:57–60.
17.Green, C. Considering the value associated with innovation in health technology appraisal decisions (deliberations): A NICE thing to do? Appl Health Econ Health Policy. 2010;8:1–5.
18.Ferner, RE, Hughes, DA, Aronson, JK. NICE and new: Appraising innovation. BMJ. 2010;340:b5493.
19.Linley, WG, Hughes, DA. Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: A cross-sectional survey of 4118 adults in Great Britain. Health Econ. 2013;22:948–964.
20.Rawlins, M, Barnett, D, Stevens, A. Pharmacoeconomics: NICE's approach to decision-making. Br J Clin Pharmacol. 2010;70:346–349.
21.Heible, C. Pharmacologic-technical progress and the economics of growth. Pharm Policy Law. 2013;15:103–125.
22.Sorescu, AB, Chandy, RK, Prabhu, JC. Sources and financial consequences of radical innovation: Insights from pharmaceuticals. J Mark. 2003;67:82–102.
23.Sternitzke, C. Knowledge sources, patent protection, and commercialization of pharmaceutical innovations. Res Policy. 2010;39:810–821.
24.Adami, S, Ciampalini, S, Dell'Aera, M, et al. Defining innovations of therapeutic interventions: A position paper by the Italian Society of Hospital Pharmacists. Int J Clin Pharm. 2012;34:259–262.
25.Alexander, GC, O'Connor, AB, Stafford, RS. Enhancing prescription drug innovation and adoption. Ann Intern Med. 2011;154:833–837.
26.Barbui, C, Cipriani, A, Lintas, C, et al. CNS drugs approved by the centralised European procedure: True innovation or dangerous stagnation? Psychopharmacology (Berl). 2007;190:265–268.
27.Caprino, L, Russo, P. Developing a paradigm of drug innovation: An evaluation algorithm. Drug Discov Today. 2006;11:999–1006.
28.Gonzalez, SS, Hofer, JM. FDA's “Breakthrough” drug therapy designation: A real regulatory breakthrough for innovations? Part 1. Pharm Ind. 2015;77:801–808.
29.Gridchyna, I, Aulois-Griot, M, Maurain, C, Bégaud, B. How innovative are pharmaceutical innovations? The case of medicines financed through add-on payments outside of the French DRG-based hospital payment system. Health Policy. 2012;104:69–75.
30.Erice statement on drug innovation. Br J Clin Pharmacol. 2008;65:440–441.
31.Joppi, R, Bertele, V, Garattini, S. Disappointing biotech. BMJ. 2005;331:895–897.
32.Kwong, WJ, Norton, EC. The effect of advertising on pharmaceutical innovation. Rev Ind Organ. 2007;31:221–236.
33.Lexchin, J. International comparison of assessments of pharmaceutical innovation. Health Policy. 2012;105:221–225.
34.Morgan, S, Lopert, R, Greyson, D. Toward a definition of pharmaceutical innovation. Open Med. 2008;2:e4-e7.
35.O'Connor, DJ, McDonald, K, Lam, SP. A regulator's guide to the UK early access to medicines scheme. Regul Rapp. 2016;13:10–13.
36.Petrini, C. Innovative therapies: General aspects and ethical criteria for evaluating protocols. Clin Ter. 2013;164:e53-e61.
37.Puntmann, I, Schmacke, N, Melander, A, et al. EVITA: A tool for the early evaluation of pharmaceutical innovations with regard to therapeutic advantage. BMC Clin Pharmacol. 2010;10:5.
38.Raymond, AS. EMA initiatives for innovation. Pharm Policy Law. 2010;12:15–18.
39.Salter, B, Zhou, Y, Datta, S. Hegemony in the marketplace of biomedical innovation: Consumer demand and stem cell science. Soc Sci Med. 2015;131:156–163.
40.Soleimani, F, Zenios, S. Disrupting incrementalism in health care innovation. Ann Surg. 2011;254:203–208.
41.Wardell, WM, DiRaddo, J. The measurement of pharmaceutical innovation. J Clin Pharmacol. 1980;20:1–9.
42.Nelson, AL, Cohen, JT, Greenberg, D, Kent, DM. Much cheaper, almost as good: Decrementally cost-effective medical innovation. Ann Intern Med. 2009;151:662–667.
43.Cadranel, J, Créquit, P, Vieira, T, et al. How to provide an equal access to innovative therapies? Rev Mal Respir Actualites. 2015;7:462–475.
44.Gonçalves, A, Maraninchi, D, Marino, P. Anticancer drugs: Which prices for therapeutic innovations? Bull Cancer. 2016;103:361–367.
45.Autret-Leca, E. Most innovative drugs labelled during the last years in paediatrics: Does the paediatrician have the tools for their identification? Arch Pediatr. 2010;17:1237–1242.
54.Berwick, DM. Disseminating innovations in health care. JAMA. 2003;289:1969–1975.
55.Schlander, M, Garattini, S, Kolominsky-Rabas, P, et al. Determining the value of medical technologies to treat ultra-rare disorders: A consensus statement. J Mark Access Health Policy. 2016. doi:10.3402/jmahp.v4.33039.
56.Toumi, M, Jadot, G. Economic impact of new active substance status on EU payers’ budgets: Example of dimethyl fumarate (Tecfidera®) for multiple sclerosis. J Mark Access Health Policy. 2014. doi:10.3402/jmahp.v2.23932.